Keywords
Radioisotopes/therapeutic use
iodine-131
Dosimetry
How to Cite
Abstract
Although used for decades, there is no consensus on the ideal 131I activity to be administered in radioiodine therapy-RIT of hyperthyroidism due to Graves disease-HDG. Objectives: To establish a standard for dosimetry in RIT of HDG and to determine dosimetric and clinical variables related to therapeutic success. Results: better standardization of dosimetry, recommending USG for volume measurements. The dosimetry can be used in RIT planning, with a target of 300 Gy, with an increase in the target for elderly or high-volume goiter. Discussion: the improvement of the methods for dosimetry application in RIT planning was appropriately transferred from the PPSUS project to the clinical routine. In addition to paper publications and talks, it should be noticed that HCFMUSP is a training center with a national impact in the dissemination of knowledge in the specialty, so that residents formed carry the concepts of dosimetry guided RIT in their future activities. The need for a deepening of internal dosimetry concepts by the training physicians has been worked together with medical physics professionals, increasing knowledge through the creation of stages, courses and discussions. Externally, the faculty participates in Congresses with subjects related to dosimetry with the same purpose.
References
1. Andrade VA, Gross JL, Maia AL. Tratamento do hipertireoidismo da Doença de Graves. Arq Bras Endocrinol Metab. 2001;45(6):609–18.
2. Cooper DS. Hyperthyroidism. Lancet. 2003 Aug 9;362(9382):459–68.
3. Wartofsky L, Glinoer D, Solomon B, Nagataki S, Lagasse R, Nagayama Y, et al. Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States. Thyroid. 1991;1(2):129–35.
4. Sapienza MT, Coura-Filho GB, Willegaignon J, Watanabe T, Duarte PS, Buchpiguel CA. Clinical and Dosimetric Variables Related
to Outcome After Treatment of Graves’ Disease With 550 and 1110 MBq of 131I: Results of a Prospective Randomized Trial. Clin Nucl Med. 2015 Sep;40(9):715–9.
5. Hironaka FH, Ono CR, Buchpiguel CA. Medicina nuclear: princípios e aplicações [2. 2017; Available from: https://observatorio. fm.usp.br/handle/OPI/55383
6. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005;294(1):71–80.
7. Peters H, Fischer C, Bogner U, Reiners C, Schleusener H. Radioiodine therapy of Graves’ hyperthyroidism: standard vs. calculated
131iodine activity. Results from a prospective, randomized, multicentre study. Eur J Clin Invest. 1995;25(3):186–93.
8. Willegaignon J, Sapienza MT, Coutinho AMN, Pitella FA, Buchpiguel CA, Reis HR. Estimativa de dose absorvida de radiação em medula óssea durante a radioiodoterapia da doenca de Graves. Congresso Brasileiro de Biologia Medicina Nuclear e Imagem Molecular [i nternet]. 2008;41. Available from: https://repositorio.usp.br/item/002496858
9. Bacher K, Thierens HM. Accurate dosimetry: an essential step towards good clinical practice in nuclear medicine. Nucl Med Commun. 2005 Jul;26(7):581–6.
10. Grosso M, Traino A, Boni G, Banti E, Della Porta M, Manca G, et al. Comparison of different thyroid committed doses in radioiodine therapy for Graves’ hyperthyroidism. Cancer Biother Radiopharm. 2005 Apr;20(2):218–23.
11. Leslie WD, Ward L, Salamon EA, Ludwig S, Rowe RC, Cowden EA. A randomized comparison of radioiodine doses in Graves’ hyperthyroidism. J Clin Endocrinol Metab. 2003 Mar;88(3):978–83.
12. Yau JSY, Chu KS, Li JKY, Chan KW, Lau IT, Yum SW, et al. Usage of a fixed dose of radioactive iodine for the treatment of
hyperthyroidism: one-year outcome in a regional hospital in Hong Kong. Hong Kong Med J. 2009 Aug;15(4):267–73.
13. Boelaert K, Syed AA, Manji N, Sheppard MC, Holder RL, Gough SC, et al. Prediction of cure and risk of hypothyroidism in
patients receiving 131I for hyperthyroidism. Clin Endocrinol (Oxf). 2009 Jan;70(1):129–38.
14. Gupta SK, McGrath S, Rogers K, Attia J, Lewis G, Viswanathan S, et al. Fixed dose (555 MBq; 15 mCi) radioiodine for the treatment of hyperthyroidism: outcome and its predictors. Intern Med J. 2010 Dec;40(12):854–7.
15. Kobe C, Weber I, Eschner W, Sudbrock F, Schmidt M, Dietlein M, et al. Graves’ disease and radioiodine therapy. Is success of ablation dependent on the choice of thyreostatic medication? Nuklearmedizin. 2008;47(4):153–6.
16. Lind P. Strategies of radioiodine therapy for Graves’ disease. Eur J Nucl Med Mol Imaging. 2002 Aug;29 Suppl 2:S453–7.
17. Reinartz P, Zimny M, Schaefer W, Mueller B, Buell U, Sabri O. Radioiodine therapy in patients with hyperthyroid disorder:
standard versus dosimetric activity application. Nucl Med Commun. 2003 Dec;24(12):1247–53.
18. Schiavo M, Bagnara MC, Calamia I, Bossert I, Ceresola E, Massaro F, et al. A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves’ disease: need to retarget the radiation committed dose to the thyroid. J Endocrinol Invest. 2011;34(3):201–5.
19. Reinhardt MJ, Brink I, Joe AY, Von Mallek D, Ezziddin S, Palmedo H, et al. Radioiodine therapy in Graves’ disease based on tissue-absorbed dose calculations: effect of pre-treatment thyroid volume on clinical outcome. Eur J Nucl Med Mol Imaging. 2002;29(9):1118–24.
20. Liu CJ, Dong YY, Wang YW, Wang KH, Zeng QY. Efficiency analysis of using tailored individual doses of radioiodine and fine tuning using a low-dose antithyroid drug in the treatment of Graves’ disease. Nucl Med Commun. 2011;32(3):227–32.
21. Meier DA, Brill DR, Becker DV, Clarke SEM, Silberstein EB, Royal HD, et al. Procedure guideline for therapy of thyroid disease
with (131)iodine. J Nucl Med. 2002;43(6):856–61.
22. de Rooij A, Vandenbroucke JP, Smit JWA, Stokkel MPM, Dekkers OM. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis. Eur J Endocrinol. 2009;161(5):771–7.
23. Stokkel MPM, Handkiewicz Junak D, Lassmann M, Dietlein M, Luster M. EANM procedure guidelines for therapy of benign thyroid disease. Eur J Nucl Med Mol Imaging. 2010;37(11):2218–28.
24. Vieira LO, Kubo R, Sapienza MT. Correlação entre volume tireoidiano determinado pelo método de ultrassonografia versus
cintilografia e sua implicação em cálculos dosimétricos na terapia com …. de Endocrinologia & … [Internet]. Available from:
https://www.scielo.br/j/abem/a/YC7XD7Z69fvBp8Jkvdy9J6f/
25. Haase A, Bähre M, Lauer I, Meller B, Richter E. Radioiodine therapy in Graves’ hyperthyroidism: determination of individual optimum target dose. Exp Clin Endocrinol Diabetes. 2000;108(2):133–7.
26. Kobe C, Eschner W, Wild M, Rahlff I, Sudbrock F, Schmidt M, et al. Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I? Nucl Med Commun. 2010;31(3):201–5.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Marcelo Tatit Sapienza, Carlos Alberto Buchpiguel, Tomoco Watanabe, José Willegaignon de Amorim de Carvalho